(NASDAQ: NVCT) Nuvectis Pharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Nuvectis Pharma's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast NVCT's revenue for 2027 to be $1,117,836,718, with the lowest NVCT revenue forecast at $1,117,836,718, and the highest NVCT revenue forecast at $1,117,836,718. On average, 1 Wall Street analysts forecast NVCT's revenue for 2028 to be $2,639,203,429, with the lowest NVCT revenue forecast at $2,639,203,429, and the highest NVCT revenue forecast at $2,639,203,429.
In 2029, NVCT is forecast to generate $3,600,496,807 in revenue, with the lowest revenue forecast at $3,600,496,807 and the highest revenue forecast at $3,600,496,807.